1. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020; 55(6):105948. [DOI:10.1016/j.ijantimicag.2020.105948] [PMID] [PMCID] [
DOI:10.1016/j.ijantimicag.2020.105948]
2. Zhao S, Chen H. Modeling the epidemic dynamics and control of COVID-19 outbreak in China. Quant Biol. 2020; 1-19. [DOI: 10.1007/s40484-020-0199-0] [PMCID] [PMID] [
DOI:10.1007/s40484-020-0199-0]
3. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708-20. https://www.nejm.org/doi/full/10.1056/nejmoa2002032 [
DOI:10.1056/NEJMoa2002032]
4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3] [PMID] [PMCID] [
DOI:10.1016/S0140-6736(20)30566-3]
5. Takian A, Raoofi A, Kazempour-Ardebili S. COVID-19 battle during the toughest sanctions against Iran. Lancet. 2020; 395(10229):1035-6. [DOI:10.1016/S0140-6736(20)30668-1] [
DOI:10.1016/S0140-6736(20)30668-1]
6. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019: Disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020: 55(4):105946. [DOI:10.1016/j.ijantimicag.2020.105946] [PMID] [PMCID] [
DOI:10.1016/j.ijantimicag.2020.105946]
7. Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: A population-based estimate using health claims data. Neurology. 2019; 92(10):e1029-40. [DOI:10.1212/WNL.0000000000007035] [PMID] [PMCID] [
DOI:10.1212/WNL.0000000000007035]
8. Ebrahimi H, Hassankhani H, Namdar H, Khodadadi E, Ferguson C. Experiences of Iranian family caregivers supporting individuals with multiple sclerosis: A qualitative study. Int J Med Res Health Sci. 2016; 5(9):174-82. https://www.ijmrhs.com/medical-research/experiences-of-iranian-family-caregivers-supporting-individuals-with-multiplesclerosis-a-qualitative-study.pdf [
DOI:10.5455/jrmds.2017513]
9. Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017; 19(1):1-10. [DOI:10.22074/cellj.2016.4867] [PMID] [PMCID]
10. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372(9648):1502-17. [DOI:10.1016/S0140-6736(08)61620-7] [
DOI:10.1016/S0140-6736(08)61620-7]
11. Hosseinzadeh A, Baneshi MR, Sedighi B, Kermanchi J, Haghdoost AA. Incidence of multiple sclerosis in Iran: A nationwide, population-based study. Public Health. 2019; 175:138-44. [DOI:10.1016/j.puhe.2019.07.013] [PMID] [
DOI:10.1016/j.puhe.2019.07.013]
12. Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020; 77(2):184-91. [DOI:10.1001/jamaneurol.2019.3365] [PMID] [PMCID] [
DOI:10.1001/jamaneurol.2019.3365]
13. Karamyan A, Dünser MW, Wiebe DJ, Pilz G, Wipfler P, Chroust V, et al. Critical illness in patients with multiple sclerosis: A matched case-control study. PLoS One. 2016; 11(5):e0155795. [DOI:10.1371/journal.pone.0155795] [PMID] [PMCID] [
DOI:10.1371/journal.pone.0155795]
14. Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol. 2013; 20(8):1153-60. [DOI:10.1111/ene.12130] [PMID] [
DOI:10.1111/ene.12130]
15. Steelman AJ. Infection as an environmental trigger of Multiple Sclerosis disease exacerbation. Front Immunol. 2015; 6:520. [DOI:10.3389/fimmu.2015.00520] [PMID] [PMCID] [
DOI:10.3389/fimmu.2015.00520]
16. Societa Italiana di Neurologia (SIN). [Indicazioni sulla gestione del paziente con SM nel corso di epidemia da Covid 19 (Italian)] [Internet]. 2021. Available from: https://www.aism.it/sites/default/files/ComunicazioneGdSSINSM-Coronavirus.pdf
17. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol. 1994; 36(suppl 1):S25-8. [DOI:10.1002/ana.410360709] [PMID] [PMCID] [
DOI:10.1002/ana.410360709]
18. Sahraian MA, Gheini MR, Rezaeimanesh N, Ghajarzadeh M, Naser Moghadasi A. Knowledge regarding COVID-19 pandemic in patients with Multiple Sclerosis (MS): A report from Iran. Mult Scler Relat Disord. 2020; 42:102193. [DOI:10.1016/j.msard.2020.102193] [PMID] [PMCID] [
DOI:10.1016/j.msard.2020.102193]
19. Dehghan A, Memarian R. Abundance of stress, anxiety and depression in Multiple Sclerosis patients. Alborz University Medical Journal. 2013; 2(2):82-8. [DOI:10.18869/acadpub.aums.2.2.82] [
DOI:10.18869/acadpub.aums.2.2.82]
20. Talaat F, Ramadan I, Aly S, Hamdy E. Are Multiple Sclerosis patients and their caregivers more anxious and more committed to following the basic preventive measures during the COVID-19 pandemic? Mult Scler Relat Disord. 2020; 46:102580. [DOI:10.1016/j.msard.2020.102580] [PMID] [PMCID] [
DOI:10.1016/j.msard.2020.102580]
21. Ghajarzadeh M, Naser Moghadasi A, Navardi S, Mohammadi A, Hamtaee S, et al. Attitude and knowledge of patients with Multiple Sclerosis (MS) About COVID-19 as provided by physicians. Arch Neurosci. 2021; 8(1):e112867. [DOI:10.5812/ans.112867] [
DOI:10.5812/ans.112867]
22. Shaygannejad V, Afshari-Safavi A, Hatef B. Assessment of mental health, knowledge, and attitude of patients with Multiple Sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus. Neurol Sci. 2021; 42(7):2891-901. [DOI:10.1007/s10072-020-04905-5] [PMID] [PMCID] [
DOI:10.1007/s10072-020-04905-5]
23. Yoo JH, Hong ST. The outbreak cases with the novel coronavirus suggest upgraded quarantine and isolation in Korea. J Korean Med Sci. 2020; 35(5):e62. [DOI:10.3346/jkms.2020.35.e62] [PMID] [PMCID] [
DOI:10.3346/jkms.2020.35.e62]
24. Goh KT, Cutter J, Heng BH, Ma S, Koh BKW, Kwok C, et al. Epidemiology and control of SARS in Singapore. Ann Acad Med Singap. 2006; 35(5):301-16. [PMID]
25. Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, et al. Disease-modifying drugs for Multiple Sclerosis and infection risk: A cohort study. J Neurol Neurosurg Psychiatry. 2018; 89(10):1050-6. [DOI:10.1136/jnnp-2017-317493] [PMID] [
DOI:10.1136/jnnp-2017-317493]
26. Solaro C, Trabucco E, Signori A, Martinelli V, Radaelli M, Centonze D, et al. Depressive symptoms correlate with disability and disease course in Multiple Sclerosis patients: An Italian multi-center study using the beck depression inventory. PLoS One. 2016; 11(9):e0160261. [DOI:10.1371/journal.pone.0160261] [PMID] [PMCID] [
DOI:10.1371/journal.pone.0160261]
27. Mateen FJ, Rezaei S, Alakel N, Gazdag B, Kumar AR, Vogel A. Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to Multiple Sclerosis: A survey of knowledge, attitudes, and practices. J Neurol. 2020; 267(12):3467-75. [DOI:10.1007/s00415-020-10045-9] [PMID] [PMCID] [
DOI:10.1007/s00415-020-10045-9]